Novacyt (ALNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novacyt (ALNOV) has a cash flow conversion efficiency ratio of -0.067x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.74 Million ≈ $-3.20 Million USD) by net assets (€40.84 Million ≈ $47.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Novacyt - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Novacyt's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALNOV current and long-term liabilities for a breakdown of total debt and financial obligations.
Novacyt Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novacyt ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KD Chem Co. Ltd
KQ:221980
|
0.024x |
|
Marco Holdings Bhd
KLSE:3514
|
0.057x |
|
PLANETEL SPA
F:0A7
|
N/A |
|
Green Critical Minerals Ltd
AU:GCM
|
-0.032x |
|
GeneBioTech Co. Ltd
KQ:086060
|
0.072x |
|
Wulff-Yhtiot Oy
HE:WUF1V
|
0.164x |
|
The Peria Karamalai Tea & Produce Company Limited
NSE:PKTEA
|
-0.004x |
|
Manaksia Aluminium Company Limited
NSE:MANAKALUCO
|
-0.083x |
Annual Cash Flow Conversion Efficiency for Novacyt (2010–2024)
The table below shows the annual cash flow conversion efficiency of Novacyt from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Novacyt (ALNOV) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €47.88 Million ≈ $55.98 Million |
€-9.82 Million ≈ $-11.48 Million |
-0.205x | +28.38% |
| 2023-12-31 | €87.24 Million ≈ $102.00 Million |
€-24.99 Million ≈ $-29.22 Million |
-0.286x | -140.40% |
| 2022-12-31 | €115.22 Million ≈ $134.70 Million |
€-13.73 Million ≈ $-16.05 Million |
-0.119x | -207.71% |
| 2021-12-31 | €141.81 Million ≈ $165.80 Million |
€15.69 Million ≈ $18.34 Million |
0.111x | -83.81% |
| 2020-12-31 | €150.71 Million ≈ $176.20 Million |
€102.98 Million ≈ $120.39 Million |
0.683x | +1029.33% |
| 2019-12-31 | €12.47 Million ≈ $14.58 Million |
€-916.70K ≈ $-1.07 Million |
-0.074x | -18.83% |
| 2018-12-31 | €18.15 Million ≈ $21.22 Million |
€-1.12 Million ≈ $-1.31 Million |
-0.062x | +66.82% |
| 2017-12-31 | €22.12 Million ≈ $25.86 Million |
€-4.12 Million ≈ $-4.82 Million |
-0.186x | -29.43% |
| 2016-12-31 | €15.15 Million ≈ $17.71 Million |
€-2.18 Million ≈ $-2.55 Million |
-0.144x | +71.63% |
| 2015-12-31 | €7.77 Million ≈ $9.08 Million |
€-3.95 Million ≈ $-4.61 Million |
-0.508x | -1099.81% |
| 2014-12-31 | €16.04 Million ≈ $18.75 Million |
€-678.92K ≈ $-793.73K |
-0.042x | +90.85% |
| 2013-12-31 | €1.94 Million ≈ $2.27 Million |
€-897.54K ≈ $-1.05 Million |
-0.462x | -236.32% |
| 2012-12-31 | €1.34 Million ≈ $1.57 Million |
€-184.36K ≈ $-215.54K |
-0.138x | -121.29% |
| 2011-12-31 | €-744.73K ≈ $-870.67K |
€-481.00K ≈ $-562.34K |
0.646x | +1707.09% |
| 2010-12-31 | €-846.00K ≈ $-989.06K |
€34.00K ≈ $39.75K |
-0.040x | -- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more